Sabitlenmiş Tweet

Congratulations to #UMichPath researchers, Drs. Jolanta Grembecka and Tomasz Cierpicki on their recent @US_FDA approval of the first once-daily oral therapy for relapsed/refractory NPM1-mutant acute myeloid leukemia.
“This transformative discovery, grounded in research conducted in the Department of Pathology, marks an important moment for our community. The work of Drs. Grembecka and Cierpicki, now recognized through FDA approval, reflect the strength of our scientific environment and our commitment to improving care for patients. It is meaningful to see U-M Pathology contribute to a therapy that is making a real difference for those with leukemia,” said Charles Parkos, Chair of the Department of Pathology.
Read about their work: michmed.org/qNYd4

English

















